Skip to main content

In Brief This Week: Roche Diagnostics, Cedars-Sinai; Agilent; Banyan Biomarkers, Amarantus

NEW YORK (GenomeWeb News) – Roche Diagnostics said this week that Cedars-Sinai Medical Center in Los Angeles will serve as a Roche Molecular Center of Excellence for the next five years. Cedars-Sinai offers prognostic and diagnostic tools for individualized molecular testing. One of the tests it will offer as an MCE is Roche's cobas 4800 BRAF V600 Mutation Test.


Agilent Technologies has become an industry sponsor of GreenCentre Canada, a national center of excellence for commercializing green chemistry discoveries generated by academic researchers and industry. GreenCentre Canada is funded by the governments of Ontario and Canada and focuses on developing environmentally friendly alternatives to traditional chemical and manufacturing products.


Banyan Biomarkers has signed a companion diagnostic deal with Amarantus BioSciences to evaluate a potential treatment for traumatic brain injury (TBI). Banyan has developed a biomarker-based test for TBI and said that it also intends to utilize biomarkers of neurotoxicity developed by Banyan to assess the safety of Amarantus' drug.


In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Filed under

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.